FDA Suspends Licensing of Ixchiq Chikungunya Vaccine Amid Safety Concerns
The FDA suspended the biologics license for Ixchiq, the first approved chikungunya vaccine, after reports of serious adverse events and…
FDA accepts proposal for reasonably likely surrogate endpoint for ‘MASH’ all-cause mortality or liver-related events
FDA accepts proposal for reasonably likely surrogate endpoint for ‘MASH’ all-cause mortality or liver-related events
Veracyte Announces New Study Published in Cell Shows that Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)—- $VCYT–Veracyte Announces New Study in Cell Shows that Decipher Prostate Test Predicts Chemotherapy Benefit in…
Enhancing Collaboration Between Payers and Providers in Identifying and Addressing Population Health Challenges
We’ve talked about identifying and addressing population health challenges before, but with it being such a wide topic — there…
Wayfair expands logistics offering to include multichannel service
Suppliers can now tap the furniture retailer’s CastleGate network as a 3PL alternative for big-and-bulky goods across their entire customer…
Home Depot focuses on faster deliveries to boost satisfaction
Dedicated associates and machine learning-driven efficiency improvements helped the retailer achieve its fastest ever delivery speeds during the second quarter.
Target scales back on in-store fulfillment strategy
The retailer will take recent learnings about which stores are “built to fulfill” and apply it to up to 40…
Is Your Revenue Cycle Management (RCM) A Disaster?
Whenever I talk with experts in revenue cycle management, it’s amazing to hear them share how almost every hospital, health…
Timeline of Selected FDA Activities and Significant Events Addressing Substance Use and Overdose Prevention
Timeline of Selected FDA Activities and Significant Events Addressing Opioid Misuse and Abuse
FDA removes risk evaluation and mitigation strategy (REMS) program for the antipsychotic drug Clozapine
FDA removes risk evaluation and mitigation strategy (REMS) program for the antipsychotic drug Clozapine